8 active not recruiting, 7 completed, 4 terminated, 1 withdrawn. 12 Phase 1, 12 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 4, Terminated 4, Active not recruiting 3, Withdrawn 1 |
| Phase 2 | 12 | Active not recruiting 5, Completed 5, Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Stage III Cutaneous Melanoma AJCC v7: new trials by email Literature Review of Stage III Cutaneous Melanoma AJCC v7 trials Research Report on Stage III Cutaneous Melanoma AJCC v7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Laboratory Biomarker Analysis - Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 6 | 2018-06-14 | 2021-04-02 |
| Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Pembrolizumab, Talimogene Laherparepvec - Advanced Melanoma, Recurrent Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 43 | 2018-06-05 | 2026-05-20 |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery Glembatumumab Vedotin, Ipilimumab, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2018-04-20 | 2018-07-18 | |
| Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma Cryosurgery, Pembrolizumab, Pheresis - Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 7 | 2017-11-15 | 2025-06-12 |
| Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 | Completed | Mayo Clinic | 20 | 2017-01-31 | 2026-09-01 |
| Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma Binimetinib, Dabrafenib, Encorafenib - Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 52 | 2016-12-09 | 2026-06-11 |
| A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Biospecimen Collection, Computed Tomography, Echocardiography Test - Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 600 | 2015-11-23 | 2026-10-26 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma Aldesleukin, CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes, Cyclophosphamide - Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 10 | 2015-01-28 | 2024-10-08 |
| Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma Aldesleukin, Cyclophosphamide, Fludarabine Phosphate - Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 34 | 2014-10-15 | 2026-10-06 |
| Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate - Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 280 | 2014-09-19 | 2026-10-22 |
| Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Dabrafenib, Laboratory Biomarker Analysis, Onalespib - BRAF V600E Mutation Present, BRAF V600K Mutation Present | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2014-05-29 | 2024-10-16 |
| A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Recombinant Flt3 Ligand - Cutaneous Melanoma, Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2014-04-09 | 2021-11-16 |
| Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery Dabrafenib, Ipilimumab, Laboratory Biomarker Analysis - BRAF V600E Mutation Present, BRAF V600K Mutation Present | Phase 1 | Terminated | National Cancer Institute (NCI) | 15 | 2013-08-28 | 2022-03-10 |
| Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma Aldesleukin, Cyclophosphamide, Fludarabine Phosphate - Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 | Phase 2 | Completed | Fred Hutchinson Cancer Center | 11 | 2013-08-20 | 2022-11-10 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Pharmacological Study, Romidepsin - Glioma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2012-08-03 | 2025-02-07 |
| Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Akt Inhibitor MK2206, Hydroxychloroquine - Advanced Malignant Solid Neoplasm, Stage III Cutaneous Melanoma AJCC v7 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 62 | 2011-11-23 | 2026-09-09 |
| Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma Laboratory Biomarker Analysis, Pharmacological Study, Riluzole - Advanced Malignant Solid Neoplasm, Recurrent Melanoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2011-02-18 | 2026-09-15 |
| Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Aldesleukin, Laboratory Biomarker Analysis, Ziv-Aflibercept - Metastatic Melanoma, Recurrent Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 84 | 2011-01-18 | 2019-05-10 |
| Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Ipilimumab, Sargramostim - Advanced Melanoma, Metastatic Melanoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 245 | 2010-12-28 | 2026-10-01 |
Melanoma (20) · Neoplasm Metastasis (3) · Breast Neoplasms (2) · Carcinoma, Renal Cell (2) · Prostatic Neoplasms (2) · Uveal Melanoma (2) · Brain Neoplasms (1) · Colorectal Neoplasms (1) · Glioma (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Neoplasms (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1)
Neoplasms (20) · Neoplasms by Histologic Type (20) · Neoplasms by Site (20) · Neoplasms, Germ Cell and Embryonal (20) · Neoplasms, Nerve Tissue (20) · Neuroectodermal Tumors (20) · Nevi and Melanomas (20) · Skin Diseases (20) · Skin Neoplasms (20) · Skin and Connective Tissue Diseases (20) · Neuroendocrine Tumors (19) · Neoplasms, Glandular and Epithelial (3) · Neoplastic Processes (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3)
CTLA-4 Antigen (6) · Ipilimumab (6) · Nivolumab (6) · aldesleukin (4) · dabrafenib (4) · trametinib (4) · Cyclophosphamide (3) · fludarabine phosphate (3) · pembrolizumab (3) · Colony-Stimulating Factors (2) · Specimen Handling (2) · sargramostim (2) · (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (1) · Blood Component Removal (1) · CR011-vcMMAE (1)
National Cancer Institute (NCI) (13) · M.D. Anderson Cancer Center (3) · Mayo Clinic (2) · Fred Hutchinson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1)
United States (19) · Canada (2)
Frank S Hodi (2) · Matthew S. Block, M.D., Ph.D. (2) · Rodabe N Amaria (2) · Ahmad Tarhini (1) · Alain P Algazi (1) · Antoni Ribas, MD, PhD (1) · Crystal L Mackall (1) · Haeseong Park (1) · Hussein A Tawbi (1) · Janice M Mehnert (1) · Jyoti Malhotra (1) · Nina Bhardwaj (1) · Patrick A Ott (1) · Roisin M Connolly (1) · Ryan J Sullivan (1)
PMID 25369488, PMID 31401903, PMID 32192573, PMID 33020646, PMID 34416167, PMID 35121932, PMID 37036756, PMID 37042037, PMID 39863139, PMID 39967670
UM1CA186716 (3), P30CA006516 (2), P30CA015704 (2), P30CA072720 (2), U01CA062490 (2), U01CA132194 (2), U10CA180820 (2), U10CA180888 (2), UM1CA186709 (2), N01CM00038 (1), N01CM00070 (1), N01CM00071 (1), N01CM62209 (1), P30CA016042 (1), P30CA033572 (1)